'Eat the rich' vandals strike
Trapped orca eats seal meat
Hole punched in Walmart
Poland urges more spending
Cutting rates at own pace
MPs chide health agency
Full Trump jury seated
Iran fires at attack drones 
World's largest election 
TikTok testing new app
Body Shop explores sale
Apple pulls apps from China
Warriors ready for Round 2
Kalamalka Bowl cancelled
Rockets live to fight on
Hilton teams up with Sia
Swift still 'can't forgive' Kim
Grimes to ‘cap the disarray’
Business 12:37pm - 1,232 views
Photo: The Canadian Press
Staff work in a marijuana grow room that can be viewed by at the new visitors centre at Canopy Growths Tweed facility in Smiths Falls, Ontario.
Canopy Growth Corp. has signed a deal to buy a German company that specializes in cannabinoid-based medical therapies used by European physicians for roughly $342.9 million.
Under the deal, the Ontario-based company has acquired C3 Cannabinoid Compound Co.
C3's main medicinal offering is dronabinol, a compound with standardized concentrations of THC (tetrahydrocannabinol), the main psychoactive compound in cannabis.
Dronabinol is available in Austria, Denmark and Germany.
C3 has two manufacturing facilities specializing, respectively, in natural extraction and synthetic cannabinoid production.
The company's senior management team is expected to continue with the business.
